Liaoning Cheng Da Co (600739) Fair Value & Analysis
Healthcare · CN · Market cap 15.7B CNY
Fair value as of: Jun 24, 2026
Analysis
Liaoning Cheng Da Co (600739) currently trades at ¥10.74, while our model-based Fair Value estimate is ¥9.43 — implying the stock looks roughly 12.2% overvalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Liaoning Cheng Da Co., Ltd. engages in biopharmaceutical, financial investment, supply chain, energy development, and other businesses in China and internationally. The company is involved in the import and export of textiles, and clothing, as well as the trade of bulk commodities, such as coal, steel, and aquatic products; and oil shale mining, shale oil production, and sale business. It also offers financial service enterprises including securities, insurance, and funds; rabies vaccines for human use and inactivated Japanese encephalitis vaccines for human use; medical industry investment and medical enterprise management consulting; and computer software and hardware technology development, technology consulting, technology transfer, technical services, and selling of medical equipment and other businesses. The company was founded in 1991 and is headquartered in Dalian, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Liaoning Cheng Da Co (600739) undervalued?
What is the fair value of 600739?
What is the quality score of 600739?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.